Trial-by-gene · BRCA1/2

Active clinical trials enrolling BRCA-mutant ovarian cancer

Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.

BRCA-mutant ovarian cancer trials focus on (1) PARP + bevacizumab + ICI triplets, (2) post-PARP resistance combinations (ATR inhibitor, WEE1 inhibitor, immunotherapy), (3) optimal PARP duration and rechallenge strategies, and (4) HRD-positive (BRCA-wild-type) expansion trials.

See the BRCA ovarian cheat sheet.

Browse the live listing

Search ClinicalTrials.gov for actively recruiting ovarian trials with BRCA / HRR-directed interventions.

Open ClinicalTrials.gov listing

Source: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.

Representative trial phases and designs

Phase III, 1L maintenance

Olaparib + bevacizumab maintenance in HRD-positive (PAOLA-1 follow-on combinations); niraparib (PRIMA follow-on).

Phase II, post-PARP

ATR inhibitors (ceralasertib, M4344) after PARP progression.

Phase II, PARP + ICI

Niraparib or olaparib + pembrolizumab in BRCA-wild-type recurrent ovarian.

Frequently asked questions

When is HRD-positive sufficient vs BRCA-mutant required?
Depends on the trial — 1L maintenance trials increasingly accept HRD-positive (e.g., PAOLA-1 expansion). Earlier-line metastatic trials may still require BRCA-mutant specifically. Check the inclusion criteria.

Related